Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.50 |
| ▸ | PDE1A | P54750 | 7/20 | 0.48 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | PDE5A | O76074 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | PDE8A | O60658 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.42 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916725 | 0.86 | PDE4A (0.56) | PDE4APDE1APDE1BPDE5APDE2A | |
| SCHEMBL4919936 | 0.86 | PDE1A (0.56) | PDE4APDE1APDE1BPDE4BPDE4C | |
| SCHEMBL18380649 | 0.76 | PDE4A (0.45) | PDE4APDE1APDE1BPDE5APDE2A | |
| SCHEMBL4914890 | 0.76 | PDE4A (0.45) | PDE4APDE1APDE1BPDE5APDE2A | |
| SCHEMBL7881367 | 0.72 | PDE4A (0.76) | PDE4APDE1APDE1BPDE4BPDE4C | |
| SCHEMBL19158342 | 0.71 | PDE1A (0.47) | PDE4APDE1APDE1BPDE5APDE2A | |
| SCHEMBL21144927 | 0.71 | PDE4A (0.51) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL4922149 | 0.70 | PDE4A (0.46) | PDE4APDE1APDE1BPDE4BPDE4C | |
| SCHEMBL18745358 | 0.69 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL17508443 | 0.69 | PDE1A (0.79) | PDE4APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682355-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682355-B2 | Uses | CNTN1, BDNF, SMPD1 | PDE4A 44/4885PDE1A 35/4885PDE1B 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.